Literature DB >> 29206762

Soluble Epoxide Hydrolase Plays a Vital Role in Angiotensin II-Induced Lung Injury in Mice.

Wei Tao1, Ping-Song Li2, Gang Xu2, Yi Luo2, Yu-Sheng Shu3, Yong-Zhong Tao4, Liu-Qing Yang4.   

Abstract

BACKGROUND: Angiotensin II plays a vital role in the pathogenesis of acute respiratory distress syndrome (ARDS). However, its mechanism is not well defined. Angiotensin II upregulates the expression of soluble epoxide hydrolase (sEH; Ephx2). sEH is suggested as a potential pharmacologic target for ARDS. The present study investigates whether the sEH is involved in the angiotensin II-triggered pulmonary inflammation and edema using an angiotensin II-induced lung injury animal model.
METHODS: Lung injury was induced by angiotensin II intratracheally instillation in wild-type or Ephx2 deficient mice.
RESULTS: sEH activities were markedly increased in wild-type mice treated with angiotensin II. Angiotensin II markedly increased the levels of tumor necrosis factor-α and interleukin-1β in bronchoalveolar lavage fluid, worsened alveolar capillary protein leak and lung histological alterations, and elevated activity of activator protein-1 and nuclear factor-κB. However, these changes were significantly improved in Ephx2 deficient mice. Moreover, Losartan, an angiotensin II receptor 1 antagonist, abolished the sEH induction and improved mortality.
CONCLUSIONS: Angiotensin II-induced lung injury was improved in sEH gene deleted mice. The angiotensin II-triggered pulmonary inflammation is mediated, at least in part, through the sEH.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29206762     DOI: 10.1097/SHK.0000000000001067

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  10 in total

Review 1.  Inhibitors of soluble epoxide hydrolase on acute lung injury: a meta-analysis of preclinical studies.

Authors:  Wei Tao; Gang Xu; Yi Luo; Ping-Song Li
Journal:  Inflammopharmacology       Date:  2022-09-10       Impact factor: 5.093

2.  Deletion of soluble epoxide hydrolase attenuates mice Hyperoxic acute lung injury.

Authors:  Li-Ping Liu; Bin Li; Tian-Kui Shuai; Lei Zhu; Yu-Min Li
Journal:  BMC Anesthesiol       Date:  2018-04-27       Impact factor: 2.217

3.  Tanshinone IIA attenuates ovalbumin-induced airway inflammation and hyperresponsiveness in a murine model of asthma.

Authors:  Shi-Biao Wang; Xiao-Feng Guo; Bin Weng; Su-Ping Tang; Hui-Jie Zhang
Journal:  Iran J Basic Med Sci       Date:  2019-02       Impact factor: 2.699

Review 4.  Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.

Authors:  Nicholas E Ingraham; Abdo G Barakat; Ronald Reilkoff; Tamara Bezdicek; Timothy Schacker; Jeffrey G Chipman; Christopher J Tignanelli; Michael A Puskarich
Journal:  Eur Respir J       Date:  2020-07-09       Impact factor: 16.671

5.  Reduction of hyperoxic acute lung injury in mice by Formononetin.

Authors:  Yin Chen; Dong Wei; Jin Zhao; Xiangnan Xu; Jingyu Chen
Journal:  PLoS One       Date:  2021-01-07       Impact factor: 3.240

Review 6.  The Looming Effects of Estrogen in Covid-19: A Rocky Rollout.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; Hani Faidah; Thabat J Al-Maiahy; Natália Cruz-Martins; Gaber El-Saber Batiha
Journal:  Front Nutr       Date:  2021-03-18

Review 7.  CYP450 Epoxygenase Metabolites, Epoxyeicosatrienoic Acids, as Novel Anti-Inflammatory Mediators.

Authors:  Zeqi Shi; Zuowen He; Dao Wen Wang
Journal:  Molecules       Date:  2022-06-16       Impact factor: 4.927

8.  Vitexin attenuates lipopolysaccharide-induced acute lung injury by controlling the Nrf2 pathway.

Authors:  Ying Lu; Ting Yu; Jingyao Liu; Lina Gu
Journal:  PLoS One       Date:  2018-04-25       Impact factor: 3.240

9.  Interleukin-3 plays a vital role in hyperoxic acute lung injury in mice via mediating inflammation.

Authors:  Zhijian Huang; Wei Zhang; Jian Yang; Feiyu Sun; Hongwei Zhou
Journal:  BMC Pulm Med       Date:  2018-10-30       Impact factor: 3.317

10.  Prediction of repurposed drugs for treating lung injury in COVID-19.

Authors:  Bing He; Lana Garmire
Journal:  F1000Res       Date:  2020-06-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.